TP-03 met all primary and secondary endpoints in a phase 2b/3 trial and had no serious treatment-related adverse events or discontinuations in the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.
The randomized, controlled, multicenter, double-masked pivotal Saturn-1 trial investigated the safety and efficacy of TP-03 (lotilaner ophthalmic solution 0.25%) in 421 patients aged 18 years or older with Demodex blepharitis. Patients had more than 10 collarettes on the upper eyelid, at least mild erythema of the upper eyelid margin, and at least 1.5 mites